Formosa Pharmaceuticals, Inc. (6838.TWO)
Formosa Pharmaceuticals, Inc.
No. 57, Fuxing North Road
8F-6 Songshan District
Taipei 105
Taiwan
886 2 2755 7659
https://www.formosapharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Description
Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007, an aqueous-based ophthalmic nanosuspension that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002, a topical antibiotic for infectious eye diseases, such as blepharitis; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer, as well as lung fibrosis. It has a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutic. The company was founded in 2010 and is headquartered in Taipei City, Taiwan.
Corporate governance
Formosa Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
